Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, announced the newest addition to its CN-Series, the CN-9000 Automated Hemostasis Solution.
Dymicron®, a privately held medical device company pioneering advanced spinal technologies, announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial.
Grady Health System announced that Christine Guillory has been named Chief Legal Officer, effective January 12, 2026. Guillory succeeds Tim Jefferson, who retired at the end of 2025 after more than 25 years of dedicated service to Grady.
MEDITECH has announced the go-live of the first large-scale wave of its enterprise-wide MEDITECH Expanse EHR implementations at HCA Healthcare, one of the nation’s leading providers of healthcare.
Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), announces that it has received product 510(k) Marketing Clearance from the US Food and Drug Administration ("FDA") for its VaporShield ™ CSTD.
Hologic, Inc. a leading medical technology company dedicated to improving women’s health, announced new data that highlights how the company’s advanced AI-powered mammography solution can aid in detecting more breast cancers.
Teal Health, a virtual women's health platform and the creators of the first and only FDA-authorized self-collection device for at-home cervical cancer screening, announced the availability of their services on the Thatch Marketplace.
Bruker Corporation announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry.
EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world's first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.
Wingderm® announces that its Renuva 1550nm non-ablative fractional laser system has obtained MDR certification in the European Union, marking a significant regulatory milestone for the device within the EU market.